Xenogeneic transplantation

被引:363
作者
Auchincloss, H [1 ]
Sachs, DH
机构
[1] Massachusetts Gen Hosp, Surg Serv, Transplant Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Surg Serv, Transplantat Biol Res Ctr, Boston, MA 02114 USA
关键词
xenotransplants; humoral antibody rejection; tolerance; accommodation; pigs; hyperacute rejection;
D O I
10.1146/annurev.immunol.16.1.433
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This review summarizes the clinical history and rationale for xenotransplantation; recent progress in understanding the physiologic, immunologic, and infectious obstacles to the procedure's success; and some of the strategies being pursued to overcome these obstacles. The problems of xenotransplantation are complex, and a combination of approaches is required. The earliest and most striking immunologic obstacle, that of hyperacute rejection, appears to be the closest to being solved. This phenomenon depends on the binding of natural antibody to the vascular endothelium, fixation of complement by that antibody, and finally, activation of the endothelium and initiation of coagulation. Therefore, these three pathways have been targeted as sites for intervention in the process. The mechanisms responsible for the next immunologic barrier, that of delayed xenograft/acute vascular rejection, remain to be fully elucidated. They probably also involve multiple pathways, including antibody and/or immune cell binding and endothelial cell activation. The final immunologic barrier, that of the cellular immune response, involves mechanisms that are similar to those involved in allograft rejection. However, the strength of the cellular immune response to xenografts is so great that it is unlikely to be controlled by the types of nonspecific immunosuppression used routinely to prevent allograft rejection. For this reason, it may be essential to induce specific immunologic unresponsiveness to at least some of the most antigenic xenogeneic molecules.
引用
收藏
页码:433 / 470
页数:38
相关论文
共 202 条
  • [1] Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients
    Aebischer, P
    Schluep, M
    Deglon, N
    Joseph, JM
    Hirt, L
    Heyd, B
    Goddard, M
    Hammang, JP
    Zurn, AD
    Kato, AC
    Regli, F
    Baetge, EE
    [J]. NATURE MEDICINE, 1996, 2 (06) : 696 - 699
  • [2] HUMORAL TOLERANCE IN XENOGENEIC BMT RECIPIENTS CONDITIONED BY A NONMYELOABLATIVE REGIMEN
    AKSENTIJEVICH, I
    SACHS, DH
    SYKES, M
    [J]. TRANSPLANTATION, 1992, 53 (05) : 1108 - 1114
  • [3] AKSENTIJEVICH I, 1991, J IMMUNOL, V147, P4140
  • [4] Xenotransplantation at a crossroads: Prevention versus progress
    Allan, JS
    [J]. NATURE MEDICINE, 1996, 2 (01) : 18 - 21
  • [5] CELLULAR BASIS OF THE PROLIFERATIVE RESPONSE OF HUMAN T-CELLS TO MOUSE XENOANTIGENS
    ALTER, BJ
    BACH, FH
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 171 (01) : 333 - 338
  • [6] Identification of porcine membrane antigens involved in the cytotoxic response mediated by human xenoreactive antibodies
    Aspeslet, LJ
    Chackowsky, P
    Sekhon, H
    Malcolm, AJ
    Mosleh, Z
    Koshal, A
    Yatscoff, RW
    [J]. XENOTRANSPLANTATION, 1996, 3 (01) : 1 - 10
  • [7] THE ROLE OF INDIRECT RECOGNITION IN INITIATING REJECTION OF SKIN-GRAFTS FROM MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II-DEFICIENT MICE
    AUCHINCLOSS, H
    LEE, R
    SHEA, S
    MARKOWITZ, JS
    GRUSBY, MJ
    GLIMCHER, LH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) : 3373 - 3377
  • [8] XENOGENEIC TRANSPLANTATION - A REVIEW
    AUCHINCLOSS, H
    [J]. TRANSPLANTATION, 1988, 46 (01) : 1 - 20
  • [9] Accommodation of vascularized xenografts: Expression of ''protective genes'' by donor endothelial cells in a host Th2 cytokine environment
    Bach, FH
    Ferran, C
    Hechenleitner, P
    Mark, W
    Koyamada, N
    Miyatake, T
    Winkler, H
    Badrichani, A
    Candinas, D
    Hancock, WW
    [J]. NATURE MEDICINE, 1997, 3 (02) : 196 - 204
  • [10] BACH FH, 1992, TRANSPLANT REV, V6, P163